Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.

Detalles Bibliográficos
Autores principales: Lauder, Sarah N., Vanhaesebroeck, Bart, Gallimore, Awen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368216/
https://www.ncbi.nlm.nih.gov/pubmed/33824480
http://dx.doi.org/10.1038/s41416-021-01285-1
Descripción
Sumario:Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.

Ejemplares similares